Regeneron has received a second complete response letter from the FDA for odronextamab and anticipates delays for Eylea HD ...

Serina Therapeutics, Inc. ("Serina") (NYSE American: SER), a clinical-stage biotechnology company advancing its lead IND candidate, SER-252, for advanced ...

In fact, in the 2023–2024 SHRM State of the Workplace Report, approximately half of workers report feeling used up (51%), ...

Operator: Good afternoon, and welcome to the Cumberland Pharmaceuticals Second Quarter 2025 Financial Report and Company ...

Q2 2025 Management View CEO David L. Hallal emphasized Scholar Rock is “scaling for the next phase of growth as a commercial stage fully integrated global biopharmaceutical company.” He outlined three ...

Topline results were announced from a second phase 3 trial evaluating AD109 (aroxybutynin 2.5mg/atomoxetine 75mg) in patients with obstructive sleep apnea (OSA).

Abivax Announces Positive Phase 3 Results from Both ABTECT 8-Week Induction Trials Investigating Obefazimod, its First-in-Class Oral miR-124 Enhancer, in Moderate to Severely Active Ulcerative Colitis ...

PIVOT-PO Phase 3 trial evaluating tebipenem Hbr in complicated urinary tract infection (cUTI) patients stopped early for efficacy following review by independent data monitoring committee (IDMC)Spero ...

The Ashes of Creation Alpha 2 Phase 3 release date is pushed back, as developer Intrepid polishes the ambitious new MMORPG’s next update.

Roche’s hopes of getting astegolimab to regulators this year took a hit after the anti-ST2 antibody failed to reduce flare-ups in a phase 3 study.

Phase 3 OASISplus data demonstrating benefit of donidalorsen for HAE patients who switched from other prophylactics published in JACI In Practice Provided by Business Wire Jul 21, 2025, 4:00:00 AM ...

Lyell Immunopharma's LYL314 CAR-T therapy shows durable responses in advanced LBCL patients. Learn about trials and upcoming milestones.